Viral Hepatitis B and C Markers in the Population of Deceased Donors in Poland

Czerwiński, Jarosław; Malanowski, P.; Wasiak, Dariusz; Pszenny, Anna; Gutowska, Dominika; Kwiatkowski, A.; Pacholczyk, Marek; Chmura, A.; Małkowski, Piotr; Wałaszewski, J

doi:10.1016/j.transproceed.2007.08.056

Cited by 7 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a number of studies reporting anti-HCV prevalence in Poland [91][92][93][94][95][96][97][98][99][100][101]. The largest study determined a viremic (RNA positive) rate of 0.60% [91].…”

Section: Hcv-infected Populationmentioning

confidence: 99%

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Saraswat

Norris

Knegt

et al. 2015

Journal of Viral Hepatitis

104

View full text Add to dashboard Cite

SUMMARY. Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8 666 000 cases) and Russia (4 162 000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become available.

show abstract

Section: Hcv-infected Populationmentioning

confidence: 99%

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Saraswat

Norris

Knegt

et al. 2015

Journal of Viral Hepatitis

104

View full text Add to dashboard Cite

show abstract

“…This high number may result from the common route of transmission for these two infections. The overall prevalence of markers of HBV infection in Poland is 16.6% and has decreased rapidly since the program of vaccinations in newborns was implemented in 1996 [13]. …”

Section: Discussionmentioning

confidence: 99%

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin

Szymanek-Pasternak¹,

Simon

Serafińska

et al. 2016

ceh

View full text Add to dashboard Cite

Aim of the studyTo determine the influence of HBsAg and HBeAg negative but anti-HBc positive status on the sustained virological response (SVR) rate in HCV-infected patients treated with pegylated interferon alfa 2 (Peg-IFNα-2) and ribavirin (RBV).Material and methodsThe study was based on the retrospective analysis of medical records of HCV-infected patients who started Peg-IFNα and RBV treatment between 1 January 2011 and 31 December 2013 at the 1st and 2nd Department of Infectious Diseases of the Regional Hospital in Wrocław, Poland.ResultsAmong 240 patients included in the analysis 99 were anti-HBc positive and 141 anti-HBc negative. In the genotype 1, anti-HBc positive group the SVR rate was 47% and in the anti-HBc negative group it was 42.7% (p = 0.591). In the genotype 3, anti-HBc positive group the SVR rate was 60% and in anti-HBc negative patients it was 63.2% (p = 0.79). Differences in SVR rates between anti-HBc positive and negative groups were not statistically significant. None of the anti-HBc positive patients developed reactivation of HBV infection during or in the 24 weeks following the end of treatment.ConclusionsAnti-HBc determination does not seem to be useful in predicting treatment outcome of conventional Peg-IFNα/RBV therapy in patients infected with HCV genotypes 1 and 3.

show abstract

“…Similar to international data, in Poland the risk groups are quite well understood and include: people who inject drugs (PWID), migrants, people in prison, transfusion recipients prior to universal donation screening before 1992, HIV positive men who have sex with men, and patients who have been hospitalized more than three times in their lives [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 91%

Injecting drug users, MSM and people at the older age should be routinely tested for HCV in Poland – data derived from a post-exposure prophylaxis population

Pyziak-Kowalska¹,

Bielecki²,

Horban³

et al. 2021

Ann Agric Environ Med.

View full text Add to dashboard Cite

Viral Hepatitis B and C Markers in the Population of Deceased Donors in Poland

Cited by 7 publications

References 4 publications

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin

Injecting drug users, MSM and people at the older age should be routinely tested for HCV in Poland – data derived from a post-exposure prophylaxis population

Contact Info

Product

Resources

About